K-pop

Ani Graduates from U.S. College… All Day Project Makes Comeback After 9 Months

New Mini-Album Release Confirmed for the 28th

KIM HYUNSIK
2026-09-14 10:41:00
[Edaily Starin KIM HYUNSIK Reporter] The mixed-gender group ALLDAY PROJECT (Annie, Tarzan, Bailey, Woo-chan, Young-seo) is making a comeback after a hiatus.
From the top left, clockwise: Ani, Tarzan, Youngseo, Bailey, Woochan (Photo courtesy of The Black Label)
According to their agency, The Black Label, on the 14th, ALLDAY PROJECT will make a comeback on the 28th with the release of their second mini-album, “CRASH.”
Since their debut last June, All Day Project has risen to the ranks of popular groups by achieving strong results on music charts with songs such as “FAMOUS,” “ONE MORE TIME,” and “LOOK AT ME.”
This marks their first new release in about nine months since they dropped their first mini-album, “All Day Project,” last December. During that time, member Annie resumed her studies and graduated from Columbia University in New York City.
Annie has garnered attention as the granddaughter of Shinsegae Group Chairwoman Lee Myung-hee and the eldest daughter of Chairwoman Jung Yoo-kyung. She majored in art history and visual arts at Columbia University and announced her graduation last May.

Economy

Corporation

IT·Science

Economy

[VC's Pick] The AI That Played a Match Against Lee Sedol 9-dan… Enhance Secures 51.2 Billion Investment

This week (September 14–18), startups in various fields—including medical artificial intelligence (AI), content solutions, and content tech—secured investments from venture capital (VC) firms and acce…
2026-09-19 09:21:04

Corporation

Kang Seong-min, CEO of PeopleBio, Inc.: “Full-Scale Launch of LDT and Diagnostic Kit Business in the U.S. … Revenue to Become Apparent Starting Next Year”

“Building on our designation as an innovative medical device by the U.S. Food and Drug Administration (FDA), we plan to establish a local subsidiary within this year. Next year, we will launch laborat…
2026-09-19 08:07:02

IT·Science

Opacalim Clinical Trials Paused… A Closer Look at the Preconditions for SK BIOPHARMACEUTICALS’s 2.3 Trillion Won Deal

SK BIOPHARMACEUTICALS(326030)has drawn attention by repeatedly emphasizing that the deal to acquire “Opacalym” (BHV-7000), a new drug candidate for epilepsy, from the U.S. biotech company Biohaven is …
2026-09-19 08:41:01